Destrier Capital Management Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Destrier Capital Management reduced its stake in Pfizer by 32.26% during the most recent quarter end. The investment management company now holds a total of 210,000 shares of Pfizer which is valued at $7,345,800 after selling 100,000 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Pfizer makes up approximately 4.58% of Destrier Capital Management’s portfolio.

Other Hedge Funds, Including , Stockman Asset Management boosted its stake in PFE in the latest quarter, The investment management firm added 5,681 additional shares and now holds a total of 121,897 shares of Pfizer which is valued at $4,263,957. Pfizer makes up approx 3.23% of Stockman Asset Management’s portfolio.Cobblestone Capital Advisors Ny reduced its stake in PFE by selling 515 shares or 1.32% in the most recent quarter. The Hedge Fund company now holds 38,581 shares of PFE which is valued at $1,367,311. Pfizer makes up approx 0.19% of Cobblestone Capital Advisors Ny’s portfolio.Agf Investments boosted its stake in PFE in the latest quarter, The investment management firm added 34,009 additional shares and now holds a total of 1,013,400 shares of Pfizer which is valued at $35,762,886. Pfizer makes up approx 0.39% of Agf Investments’s portfolio.Markston International reduced its stake in PFE by selling 7,983 shares or 3.86% in the most recent quarter. The Hedge Fund company now holds 198,620 shares of PFE which is valued at $7,319,147. Pfizer makes up approx 0.66% of Markston International’s portfolio.Salient Trust Co Lta boosted its stake in PFE in the latest quarter, The investment management firm added 7,007 additional shares and now holds a total of 235,419 shares of Pfizer which is valued at $8,635,169. Pfizer makes up approx 0.91% of Salient Trust Co Lta’s portfolio.

Pfizer opened for trading at $34.94 and hit $35.17 on the upside on Monday, eventually ending the session at $35.11, with a gain of 0.83% or 0.29 points. The heightened volatility saw the trading volume jump to 1,51,24,885 shares. Company has a market cap of $212,965 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *